Evidence map›Paper›PMID 25781937›Full record

ArticlePLoS pathogens2015

Escherichia coli α-hemolysin counteracts the anti-virulence innate immune response triggered by the Rho GTPase activating toxin CNF1 during bacteremia.

Mamady Diabate, Patrick Munro, Elsa Garcia, Arnaud Jacquel, Gregory Michel, Sandrine Obba, Diogo Goncalves, Carmelo Luci, Sandrine Marchetti, Dieter Demon and 10 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Effects of theInternational journal of molecular sciences · 2021
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Immunomodulatory properties of CNF1 toxin fromAmerican journal of cancer research · 2022
    Review
  12. Review
  13. Article
  14. Article
  15. Mobile Colistin Resistance Enzyme MCR-3 Facilitates Bacterial Evasion of Host Phagocytosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 2 countries.

Mamady DiabateINSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Toxines Microbiennes dans la relation hôte pathogènes, Nice, France; Université de Nice-Sophia-Antipolis, UFR Médecine, Nice, France; Laboratoire de Bactériologie, CHU de Nice, Hôpital l'Archet, Nice, France.
Patrick MunroINSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Toxines Microbiennes dans la relation hôte pathogènes, Nice, France; Université de Nice-Sophia-Antipolis, UFR Médecine, Nice, France.
Elsa GarciaINSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Toxines Microbiennes dans la relation hôte pathogènes, Nice, France; Université de Nice-Sophia-Antipolis, UFR Médecine, Nice, France.
Arnaud JacquelUniversité de Nice-Sophia-Antipolis, UFR Médecine, Nice, France; INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Mort Cellulaire, Differentiation et Cancer, Nice, France.
Gregory MichelINSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Toxines Microbiennes dans la relation hôte pathogènes, Nice, France; Université de Nice-Sophia-Antipolis, UFR Médecine, Nice, France.
Sandrine ObbaUniversité de Nice-Sophia-Antipolis, UFR Médecine, Nice, France; INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Mort Cellulaire, Differentiation et Cancer, Nice, France.
Diogo GoncalvesUniversité de Nice-Sophia-Antipolis, UFR Médecine, Nice, France; INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Mort Cellulaire, Differentiation et Cancer, Nice, France.
Carmelo LuciUniversité de Nice-Sophia-Antipolis, UFR Médecine, Nice, France; CNRS UMR7275, IPMC, Sophia Antipolis, France.
Sandrine MarchettiUniversité de Nice-Sophia-Antipolis, UFR Médecine, Nice, France; INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Mort Cellulaire, Differentiation et Cancer, Nice, France.
Dieter DemonDepartment of Medical Protein Research, VIB, Ghent, Belgium; Department of Biochemistry, Ghent University, Ghent, Belgium.
Clara DegosAix-Marseille University UM 2, INSERM U 1104, CNRS UMR 7280, Marseille, France.
Yassina BechahUnité de Recherche sur les Maladies Infectieuses Tropicales et Emergentes, CNRS UMR 6236, Faculté de Médecine, Marseille, France.
Jean-Louis MegeUnité de Recherche sur les Maladies Infectieuses Tropicales et Emergentes, CNRS UMR 6236, Faculté de Médecine, Marseille, France.
Mohamed LamkanfiDepartment of Medical Protein Research, VIB, Ghent, Belgium; Department of Biochemistry, Ghent University, Ghent, Belgium.
Patrick AubergerUniversité de Nice-Sophia-Antipolis, UFR Médecine, Nice, France; INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Mort Cellulaire, Differentiation et Cancer, Nice, France.
Jean-Pierre GorvelAix-Marseille University UM 2, INSERM U 1104, CNRS UMR 7280, Marseille, France.
Lynda Maria StuartBenaroya Research Institute at Virginia Mason, Seattle, Washington, United States of America.
Luce LandraudINSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Toxines Microbiennes dans la relation hôte pathogènes, Nice, France; Université de Nice-Sophia-Antipolis, UFR Médecine, Nice, France; Laboratoire de Bactériologie, CHU de Nice, Hôpital l'Archet, Nice, France.
Emmanuel LemichezINSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Toxines Microbiennes dans la relation hôte pathogènes, Nice, France; Université de Nice-Sophia-Antipolis, UFR Médecine, Nice, France.
Laurent BoyerINSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, C3M, Toxines Microbiennes dans la relation hôte pathogènes, Nice, France; Université de Nice-Sophia-Antipolis, UFR Médecine, Nice, France.
Université Côte d'Azur · FRCentre Méditerranéen de Médecine Moléculaire · FRInserm · FRCentre National de la Recherche Scientifique · FRGhent University · BEUnité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes · FRBenaroya Research InstituteCentre Hospitalier Universitaire de Nice · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The detection of the activities of pathogen-encoded virulence factors by the innate immune system has emerged as a new paradigm of pathogen recognition. Much remains to be determined with regard to the molecular and cellular components contributing to this defense mechanism in mammals and importance during infection. Here, we reveal the central role of the IL-1β signaling axis and Gr1+ cells in controlling the Escherichia coli burden in the blood in response to the sensing of the Rho GTPase-activating toxin CNF1. Consistently, this innate immune response is abrogated in caspase-1/11-impaired mice or following the treatment of infected mice with an IL-1β antagonist. In vitro experiments further revealed the synergistic effects of CNF1 and LPS in promoting the maturation/secretion of IL-1β and establishing the roles of Rac, ASC and caspase-1 in this pathway. Furthermore, we found that the α-hemolysin toxin inhibits IL-1β secretion without affecting the recruitment of Gr1+ cells. Here, we report the first example of anti-virulence-triggered immunity counteracted by a pore-forming toxin during bacteremia.

Indexed as

AnimalsBacteremiaBacterial ToxinsDisease Models, AnimalEscherichia coliEscherichia coli InfectionsEscherichia coli ProteinsFemaleHemolysin ProteinsHost-Pathogen InteractionsImmunity, InnateInterleukin-1betaMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutBacterial Toxinscytotoxic necrotizing factor type 1Escherichia coli ProteinsHemolysin ProteinsHlya protein, E coliInterleukin-1betaVirulence Factors

Identifiers

PMID25781937
PMCPMC4363529
OpenAlexW2008895707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.